shutterstock-178371752
Rawpixel / Shutterstock.com
25 March 2015Biotechnology

Case review: Biogen v Medeva, 20 years on

It may be hard to imagine Napoleon and the Duke of Wellington sitting down to reminisce after the Battle of Waterloo, and it’s perhaps just as hard to imagine warring legal parties doing so after a long and hard-fought battle. But that is what happened in February when the parties involved in the landmark patent case Biogen v Medeva met to reminisce about their involvement in the case before an invited audience.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
22 October 2025   Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
Biotechnology
2 September 2025   Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Biotechnology
12 June 2025   Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.